DXCM - デックスコム （DexCom Inc.） デックスコムDXCMのチャート
DXCMの企業情報
| symbol | DXCM |
|---|---|
| 会社名 | DexCom Inc （デックスコム） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 デクスコム（DexCom Inc.）は医療機器のメーカーである。同社は糖尿病患者および医療提供者が使用する継続的グルコースモニタリング（CGM）システムの設計、開発、および商品化に注力する。同社の製品はDexCom G4 PLATINUMとDexCom G5 Mobileで構成される。同社は第5世代CGMシステムを商業化する。同社の欧州連合（EU）、オーストラリア、ニュージーランド、アジアおよび中南米諸国、米国の米国食品医薬品局（FDA）の承認を得る同社の市場であるDexCom G4 PLATINUMをコンソーシアム・ユーロピーン・マーキング（CEマーク）のもとにある。共有リモート監視システムを備えたDexCom G4 PLATINUMは、患者の受信機と患者のiPhone、iPod touch、またはiPad上のアプリケーションとの間のワイヤレス接続を使用して、指定された受信者（フォロワー）のモバイルデバイス上のアプリケーションにグルコース情報を送信する。 デックスコムは米国の医療デバイスメ―カ―。糖尿病患者および病院用に血糖値測定器の設計、開発、商品化に従事。製品には通院患者用の｢SEVEN PLUS｣、｢DexCom G4｣、｢DexCom G4 PLATINUM｣、および病院用の｢GlucoCLear｣などがある。 DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. |
| 本社所在地 | 6340 Sequence Drive San Diego CA 92121 USA |
| 代表者氏名 | Kevin R. Sayer ケビン・R・セイヤー |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 858-200-0200 |
| 設立年月日 | 36281 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2005年 |
| 従業員数 | 2990人 |
| url | www.dexcom.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dxcm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -2.90000 |
| 終値（lastsale） | 123.395 |
| 時価総額（marketcap） | 10902655673.535 |
| 時価総額 | 時価総額（百万ドル） 10823.58 |
| 売上高 | 売上高（百万ドル） 832.50000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 10559.78 |
| 当期純利益 | 当期純利益（百万ドル） 100.30000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 DexCom Inc. revenues increased 36% to $426.9M. Net income totaled $6M vs. loss of $38.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest income increase from $700K to $3.7M (income) Research and development decrease of 1% to $92M (expense). |
DXCMのテクニカル分析
DXCMのニュース
Morgan Stanley initiates coverage of DexCom at ''equalweight'' with a price target of $131.00 2023/05/30 09:25:42 Investing.com
https://www.investing.com/news/pro/dexcom-receives-investment-bank-analyst-rating-update-3093549
LLY, DXCM, or ISRG: Which Healthcare Stock is the Most Attractive Pick? 2023/05/30 02:23:23 TipRanks
Healthcare stocks are generally more resilient in an uncertain macro backdrop, given the essential nature of products and services offered by the c…
How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring 2023/05/26 12:00:01 CNBC
CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.
DexCom Unusual Options Activity 2023/05/25 19:33:34 Benzinga
Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ: DXCM ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with DXCM, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 11 uncommon options trades for DexCom. This isn''t normal. The overall sentiment of these big-money traders is split between 72% bullish and 27%, bearish. Out of all of the special options we uncovered, 4 are puts, for a total amount of $344,068, and 7 are calls, for a total amount of $239,277. What''s The Price Target? Taking into account the Volume and Open Interest on these … Full story available on Benzinga.com
Is DexCom a go-to health care stock? [Video] 2023/05/25 08:49:21 FXStreet
DexCom, Inc. is a global company headquartered in San Diego, California, that focuses on the development, manufacturing, and distribution of continuou
Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers 2022/11/30 16:25:17 Financial Post
BURNABY, British Columbia — Dexcom, Inc. (NASDAQ: DXCM), – November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health […]
Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers 2022/11/30 16:25:00 Wallstreet:Online
Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project, as a digital
Dexcom Leads 5 Stocks Near Buy Points 2022/11/25 12:45:48 Investor''s Business Daily
Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.
Top 5 3rd Quarter Trades of Alphabet Inc. 2022/11/17 02:00:06 GuruFocus
Related Stocks: IONQ , RCUS , GTLB , VLD , DXCM ,
Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches 2022/11/14 09:00:00 Wallstreet:Online
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design site that illustrate just how unique each
Blood Glucose Meters Global Market Report 2021 Featuring Abbott, Roche, Medtronics, Ascensia and Dexcom - ResearchAndMarkets.com 2021/09/01 12:51:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Blood Glucose Meters Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com''s offering. The global blood glucose meters market is expected to grow from $2.92 billion in 2020 to $3.99 billion in 2021 at a compound annual growth rate (CAGR) of 36.6%. The market is expected to reach $4.96 billion in 2025 at a CAGR of 5.6%. Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia
Digital Diabetes Management Market to Observe Strong Expansion by 2027 | Key Players - Becton Dickinson and Company, Dexcom, Inc, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Medtronic Plc., Novo Nordisk A/S, Terumo corporation 2021/09/01 11:11:20 OpenPR
"Global Digital Diabetes Management Market Analysis to 2027" is a detailed and comprehensive report on the market, with a special focus on global market trends. market report provides the market overview, including detailed segmentation and sub-segments. It is expected that
Worldwide Remote Patient Monitoring Industry to 2026 - Featuring Abbott Laboratories, Dexcom and Medtronic Among Others - ResearchAndMarkets.com 2021/09/01 10:23:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Remote Patient Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global remote patient monitoring market reached a value of US$ 964 Million in 2020. Looking forward, the publisher expects the global remote patient monitoring market to exhibit strong growth during the next five years. Companies Mentioned Abbott Laboratories AMD Global Telemedicine Inc. B
Digital Diabetes Device Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth Opportunity and Forecast to 2027 Research Report I Top key players-Lifescan, Roche, Medtronic, Ascensia Diabetes Care, TANDEM Diabetes Care, DEXCOM, Social D 2021/08/30 11:15:37 OpenPR
Digital diabetes devices are the executives'' arrangements are cell phone associated diabetes the board gadgets and programming stages utilized by patients experiencing Type 1, Type 2, and gestational diabetes. Clinical experts likewise utilize these answers to oversee diabetes. Get sample copy
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration 2021/08/27 11:35:25 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"